


WHAT IS CLAIMED IS:

1. A compound of the formula:



- 5 wherein R represents C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆ alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, C₁-C₆ alkyl-morpholine or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein R represents C₁-C₁₀ alkyl.
- 10 3. A compound according to claim 2 wherein R represents 2-ethyl butyl, isobutyl, 3-methyl butyl, decyl, or ethyl.
4. A compound according to claim 3 wherein R represents 2-ethyl butyl,
- 15 5. A compound according to claim 3 wherein R represents isobutyl.
6. A compound according to claim 3 wherein R represents 3-methyl butyl.
- 20 7. A compound according to claim 3 wherein R represents decyl.
8. A compound according to claim 3 wherein R represents ethyl.
9. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] -
- 25 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester, or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 9 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

11. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid isobutyl ester, or a pharmaceutically acceptable salt thereof.

5

12. A compound according to claim 11 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

13. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid 3-methyl butyl ester, or a pharmaceutically acceptable salt thereof.

10

14. A compound according to claim 13 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

15

15. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid decyl ester, or a pharmaceutically acceptable salt thereof.

20

16. A compound according to claim 15 wherein the pharmaceutically acceptable salt is a trifluoroacetate salt.

17. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester, or a pharmaceutically acceptable salt thereof.

25

18. A compound according to claim 15 wherein the pharmaceutically acceptable salt is a hydrochloride salt.


30

19. A compound which is (3*S*,4*aR*,6*R*,8*aR*)-6-[2-(1*H*-Tetrazol-5-yl)-ethyl] - 1,2,3,4,4*a*,5,6,7,8,8*a*-decahydro-isoquinoline-3-carboxylic acid ethyl ester hydrochloride monohydrate.

20. A pharmaceutical composition, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.


21. A pharmaceutical composition for the treatment of pain or migraine, which comprises a compound as claimed in Claim 1 and a pharmaceutically acceptable diluent or carrier.

22. A method of treating pain, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆ alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, C₁-C₆ alkyl-morpholine or a pharmaceutically acceptable salt thereof.

23. A method of treating migraine, which comprises administering to a patient an effective amount of a compound of the formula:



wherein R represents C₁-C₂₀ alkyl, C₂-C₆ alkenyl, C₁-C₆ alkylaryl, C₁-C₆ alkyl(C₃-C₁₀)cycloalkyl, C₁-C₆ alkyl-N,N-C₁-C₆ dialkylamine, C₁-C₆ alkyl-pyrrolidine, C₁-C₆ alkyl-piperidine, C₁-C₆ alkyl-morpholine or a pharmaceutically acceptable salt thereof.

24. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of pain.

25. The use of a compound as claimed in Claim 1 for the manufacture of a medicament for the treatment of migraine.